Furthermore, use of OncoScantm detected mutations in five genes (catenin beta 1 (CTNNB1); HRas proto-oncogene, GTPase (HRAS); KRAS proto-oncogene, GTPase (KRAS); neurofibromin 2 (NF2); and SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 (SMARCB1) in HER2-positive breast cancer [82]. This evidence concerns the gene HRAS and breast carcinoma.